LRMR

Latest SEC Filings & News for LRMR

2 most recent filings and news items mentioning LRMR. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/LRMR/news?limit=20"

Pull LRMR filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
RegulatoryAug 4, 2026Positive

Larimar submits BLA for nomlabofusp, Q2 cash $156.3M

Larimar Therapeutics submitted the first module of a rolling BLA for nomlabofusp in June and reported $156.3 million in cash as of June 30, 2026, extending their runway into Q3 2027. The submission supports their bid to develop the first therapy for Friedreich's ataxia.

View filing at SEC.gov →
RegulatoryJun 29, 2026Positive

Larimar Therapeutics Submits First Module of Rolling BLA for Nomlabofusp

Larimar Therapeutics has submitted the first module of its rolling BLA to the FDA seeking accelerated approval for nomlabofusp. This submission supports the company's goal for market approval in the rare disease space with positive efficacy and safety data.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.